HUDC_VT

Phase 2Small molecule

HHaudongchun Co., Ltd.

HUDC_VT is one of 19 small molecule programs targeting Bacterial Vaginosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bacterial VaginosisActive, not recruiting

Bacterial VaginosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

65 competitors in Bacterial Vaginosis

#DrugCompanyPhaseTrials

Flagyl

DDePuy Orthopaedics

Approved

25 2

Acanya

Pfizer

Approved

3 3

Mycostatin

GGood Molecules, LLC

Approved

—4

Decadron

AAspen Global Incorporated

Approved

—5

Amoxil

GGlobal Antibiotics Research and Development Partnership

Approved

—6

Lactobacillus Acidophilus

UUniversiteit Antwerpen

Approved

1 7

Tindamax

MMission Pharmacal

Phase 3

3 8

Lactoferrin

UUniversità degli Studi di Ferrara

Phase 3

1 9

Conventional

PPopulation Health Research Institute

Phase 3

1 10

Lactoserum

Sanofi

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Bacterial Vaginosis1 trial

Clinical Study to Evaluate the Efficacy of HUDC_VT in Patients With Bacterial Vaginosis

Unknown status·HHaudongchun Co., Ltd.·Phase 2·NCT03357666·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for HUDC_VT. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HUDC_VT compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HUDC_VT. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Haudongchun Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: HHaudongchun Co., Ltd.

HUDC_VT

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Bacterial Vaginosis1 trial

References

Drug Info

Quick Facts

Related News